Xu Chunjie, Gu Lei
Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, P.R. China.
Biomed Rep. 2017 Jan;6(1):39-45. doi: 10.3892/br.2016.815. Epub 2016 Nov 18.
The microRNA, miR-196b, serves a role in normal cell differentiation, proliferation and tumorigenesis of different types of cancer. The aim of the present study was to explore the serum expression of miR-196b in colorectal cancer (CRC) and its correlation with clinicopathological features. Sera samples were obtained from 103 patients with CRC, 51 patients with colorectal adenoma (Ad) and 100 healthy individuals for the present study. The serum expression of miR-196b in sera samples of the three cohorts was detected using reverse transcription-quantitative polymerase chain reaction. The diagnostic value of miR-196b in the serum of the patients with CRC was evaluated by receiver operating characteristic (ROC) curve and survival analysis, using the Kaplan-Meier method, which was performed with the data from a 5-year follow-up. The expression of miR-196b in the serum of patients with CRC was significantly higher compared with that in Ad patients or healthy individuals (all P<0.001), and the overexpression of serum miR-196b was clearly associated with lymph node invasion, differentiation, and the tumor-lymph nodes-metastasis stage (all P<0.05). ROC curve analysis demonstrated that, comparing patients with CRC with healthy individuals, the area under the curve of serum miR-196b was 0.8135, and its specificity and sensitivity were 63 and 87.38%, respectively, at a diagnostic threshold of -4.785. Patients with CRC of miR-196b-high status had shorter overall survival and disease-free survival rates compared with those of miR-196b-low status. In conclusion, the results of the present study demonstrated that serum miR-196b is upregulated in CRC, and may have an application as a diagnostic and prognostic biomarker for patients with CRC.
微小RNA miR-196b在正常细胞分化、增殖以及不同类型癌症的肿瘤发生过程中发挥作用。本研究旨在探讨miR-196b在结直肠癌（CRC）中的血清表达及其与临床病理特征的相关性。本研究从103例CRC患者、51例大肠腺瘤（Ad）患者和100名健康个体中获取血清样本。采用逆转录-定量聚合酶链反应检测三组队列血清样本中miR-196b的表达。通过绘制受试者工作特征（ROC）曲线以及采用Kaplan-Meier法进行生存分析（该分析基于5年随访数据）来评估miR-196b在CRC患者血清中的诊断价值。CRC患者血清中miR-196b的表达显著高于Ad患者或健康个体（所有P<0.001），血清miR-196b的过表达与淋巴结浸润、分化程度以及肿瘤-淋巴结-转移分期均显著相关（所有P<0.05）。ROC曲线分析表明，将CRC患者与健康个体进行比较时，血清miR-196b的曲线下面积为0.8135，在诊断阈值为-4.785时，其特异性和敏感性分别为63%和87.38%。与miR-196b低表达状态的CRC患者相比，miR-196b高表达状态的患者总生存期和无病生存期较短。总之，本研究结果表明CRC患者血清中miR-196b上调，其可能作为CRC患者的诊断和预后生物标志物。
